Kintegral Advisory LLC Sells 18,451 Shares of Boston Scientific Corporation (NYSE:BSX)

Kintegral Advisory LLC lowered its holdings in Boston Scientific Corporation (NYSE:BSX) by 32.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,622 shares of the medical equipment provider’s stock after selling 18,451 shares during the quarter. Kintegral Advisory LLC’s holdings in Boston Scientific were worth $3,795,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in BSX. Norges Bank acquired a new position in Boston Scientific during the 4th quarter worth about $1,762,522,000. Capital World Investors raised its stake in shares of Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock worth $2,492,041,000 after acquiring an additional 6,216,199 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock worth $3,230,293,000 after purchasing an additional 3,344,571 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Boston Scientific by 11,720.3% during the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider’s stock valued at $260,057,000 after purchasing an additional 2,556,078 shares during the last quarter. Finally, Axiom Investors LLC DE increased its holdings in shares of Boston Scientific by 208.2% in the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider’s stock valued at $335,167,000 after purchasing an additional 2,535,007 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Vance R. Brown sold 4,826 shares of the company’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president owned 36,193 shares of the company’s stock, valued at $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the company’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $18,347,824.96. This trade represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 461,970 shares of company stock valued at $47,755,193 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $104.30 on Friday. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The business’s 50 day moving average price is $103.37 and its two-hundred day moving average price is $99.96. The company has a market cap of $154.30 billion, a PE ratio of 76.13, a price-to-earnings-growth ratio of 2.69 and a beta of 0.68. Boston Scientific Corporation has a twelve month low of $71.88 and a twelve month high of $107.53.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. Boston Scientific’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.56 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Morgan Stanley upped their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, May 16th. Citigroup reaffirmed a “buy” rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Barclays raised their price target on Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Needham & Company LLC reissued a “buy” rating and set a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. Finally, Evercore ISI raised their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Twenty-two analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average target price of $116.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.